CCM Duopharma Biotech Berhad and SCM Lifescience Co., Ltd. of Korea announced that they have entered into a share subscription agreement (SSA).
Whereby CCM Duopharma acquired common shares and redeemable preference convertible shares in SCM Lifescience upon and subject to the terms and conditions set out in the SSA.
IHH Healthcare Bhd, a leading premium global healthcare provider, announced yesterday that it will increase its majority equity interest in its existing Turkey subsidiary, Acibadem Holding, from 60% to approximately 90%, pursuant to the shareholders’ agreement (SHA) which was entered into in connection with IHH’s acquisition of a 60% equity interest in Acibadem Holding in 2011.
Under the SHA, Mehmet Ali Aydinlar and his wife Hatice Seher Aydinlar (collectively, “Aydinlar”) have the option to convert up to 15% equity interest held by them in Acibadem Holding into new IHH shares for a period of 10 years from 24 January 2012 (Aydinlar Option).
Technology and Talent Platform Innovator, Prestariang Bhd registered a higher revenue of RM55.9 million for its second quarter results (2QFY18) ended June 30, 2018.compared to RM55.2 million recorded in previous year corresponding quarter.
The higher revenue of RM0.7 million or 1% increase was mainly contributed by Concession revenue of Sistem Kawalan Imigresen Nasional (“SKIN”) project. The revenue was recognised based on the stage of completion at the end of the reporting period. The stage of completion is determined by reference to the proportion of costs incurred for work performed to date over the estimated total costs.